# Trial populations that skip mixed disease

Source: https://onco.cc/bottlenecks/da-bn-trial-exclusion/  
OnCo record `da-bn-trial-exclusion` (Bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Antibody trials largely enrolled people with biomarker-supported Alzheimer’s disease and excluded much mixed, vascular, and diverse disease.

## Summary

When a person has mixed pathology, atrial fibrillation, or anticoagulation, the trial result may not apply. Inclusive protocols are a proposed fix, not current practice everywhere.

## Fields

- Kind: Bottleneck
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Stage: trials
- Severity: major
- Metrics: Failure example on this atlas: ENGAGE primary endpoint not met (ClinicalTrials.gov NCT02477800)
- Causes: Strict amyloid and MRI criteria.; Under-enrolment of minoritised groups.; Exclusion of common comorbidities.

## Sources

- CLARITY AD registry: https://clinicaltrials.gov/study/NCT03887455

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mixed dementia](https://onco.cc/diagnoses/mixed-dementia/)
- ideas: [Antibody trials that enrol mixed and comorbid disease](https://onco.cc/ideas/da-idea-inclusive-anti-amyloid-trials/)

---
JSON: https://onco.cc/api/v1/entities/da-bn-trial-exclusion.json